« Payoff From Wal-Mart Turnaround Unlikely Before 2007
Ciena Needs To Sustain Operational Improvements »

Elan’s Tysabri Valued At $9 Per Share

Piper Jaffray trimmed the price target on the Irish drugmaker to $14 from $15.


From www.forbes.com/markets/2006/02/28/elan-biogen-idec-0228markets08.html?partner=rss ]]>”>Forbes Market Updates

This entry was posted on Tuesday, February 28th, 2006 at 10:00 pm and is filed under General updates. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.